Hong Kong · Delayed Price · Currency is HKD Duality Biotherapeutics Company Description
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others.
The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs.
It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC.
The company was incorporated in 2019 and is headquartered in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Zhongyuan Zhu |
Contact Details
Address: Full floor, 11th Floor Shanghai China | |
| Phone | 86 21 2601 8730 |
| Website | dualitybiologics.com |
Stock Details
| Ticker Symbol | 9606 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG2929M1087 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Zhongyuan Zhu Ph.D. | Chief Executive Officer and Chairman |
| Shaoren Zhang | Vice President of Finance and Executive Director |
| Dr. Yang Qiu | Chief Scientific Officer |
| Wen Si | Executive Director of Human Resources and Executive Director |
| Wei Gu | Chief Medical Officer |
| Xin Wang | Chief Business Officer |
| Dr. Haiqing Hua | Senior Vice President and Head of Drug Discovery |
| Xin Yu | Vice President and Head of Regulatory Affairs |
| Dr. Rong Shi | Vice President of Development Science |
| Dr. Ruiyin Chu | Vice President of Translational Medicine |